Skip to content
DraconiticResearch
Search Sources API
186,086 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Non-HLA Autoantibody-Driven Lung Allograft Injury, Clinical Course, Autoantibody Profiling, and Response to Steroid and Belatacept

  • Annika Sundlof1
  • Michiko Taniguchi2,3,4
  • Rohit Gupta5
  • Mehri Mollaee2
  • Francis Cordova5
  • Kartik Shenoy5
  • Steven Geier2,4
  • Abdelhamid Liacini2,4,6
6 affiliations
  1. 1Department of Internal Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
  2. 2Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Philadelphia, PA 19140, USA
  3. 3Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA
  4. 4Immunogenetics Laboratory, Temple University Hospital, Philadelphia, PA 19140, USA
  5. 5Department of Thoracic Medicine and Surgery, Temple University Hospital, Lewis Katz School of Medicine, Philadelphia, PA 19140, USA
  6. 6Histocompatibility Laboratory Services, American National Red Cross, 180 Rustcraft Road, Dedham, MA 02026, USA
Open at sourceDOICite

Abstract

The presence of HLA donor-specific antibodies (DSAs), both before and after transplantation, is a well-established risk factor for antibody-mediated rejection (AMR) and poor graft survival. However, emerging evidence suggests that non-HLA antibodies may also provoke immune responses, contributing to rejection. Among these, antibodies targeting the angiotensin II type-1 receptor (AT1R) have been linked to adverse clinical outcomes in kidney and orthotopic heart transplant recipients. This case presents an investigation of non-HLA antibodies in a lung transplant recipient diagnosed with AMR in the absence of HLA DSAs, as well as the use of belatacept as part of a combination immunosuppressive regimen to treat AMR in a lung transplant recipient.

Related

  1. Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
    Yueqi Wang, Siqi Wang, Huijuan Fan +6
    ImmunotherapyPeer-reviewedLicence not statedFull textNeurologyPMC
  2. Integrative pan-cancer and clinical cytokine profiling reveals a pro-inflammatory cytokine index for colon cancer peritoneal metastasis and immunotherapy response
    Caihong Wu, Xin Li, Dan Wang +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Review on the significance and clinical application of anti-p53 autoantibody detection
    Fan Bu, Zhe-Nan Ling, Pei Li +14
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. The clinical significance of baseline lung allograft dysfunction in single and bilateral lung transplant recipients
    Shahrzad M. Lari, Helen Liang, Behzad Dadfar +16
    JHLT openPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  5. An exploratory analysis of circulating cytokine profiles, pain-associated transcripts and autoantibody responses associated with treatment response in knee osteoarthritis
    S. Franks, A. Kouraki, T. Kelly +4
    medRxivPreprintCC BYFull textSurgery & anaesthesiamedRxiv

Cite

BibTeXRIS
BibTeX
@article{sundlof2026nonhla,
  title = {{Non-HLA Autoantibody-Driven Lung Allograft Injury, Clinical Course, Autoantibody Profiling, and Response to Steroid and Belatacept}},
  author = {Annika Sundlof and Michiko Taniguchi and Rohit Gupta and Mehri Mollaee and Francis Cordova and Kartik Shenoy and Steven Geier and Abdelhamid Liacini},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = oct,
  doi = {10.3390/ijms27219424},
  url = {https://www.mdpi.com/1422-0067/27/21/9424},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Non-HLA Autoantibody-Driven Lung Allograft Injury, Clinical Course, Autoantibody Profiling, and Response to Steroid and Belatacept
AU  - Annika Sundlof
AU  - Michiko Taniguchi
AU  - Rohit Gupta
AU  - Mehri Mollaee
AU  - Francis Cordova
AU  - Kartik Shenoy
AU  - Steven Geier
AU  - Abdelhamid Liacini
PY  - 2026
DA  - 2026/10/22
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms27219424
UR  - https://www.mdpi.com/1422-0067/27/21/9424
AB  - The presence of HLA donor-specific antibodies (DSAs), both before and after transplantation, is a well-established risk factor for antibody-mediated rejection (AMR) and poor graft survival. However, emerging evidence suggests that non-HLA antibodies may also provoke immune responses, contributing to rejection. Among these, antibodies targeting the angiotensin II type-1 receptor (AT1R) have been linked to adverse clinical outcomes in kidney and orthotopic heart transplant recipients. This case presents an investigation of non-HLA antibodies in a lung transplant recipient diagnosed with AMR in the absence of HLA DSAs, as well as the use of belatacept as part of a combination immunosuppressive regimen to treat AMR in a lung transplant recipient.
SN  - 1422-0067
ER  -